Status:
COMPLETED
6-Session Treatment for Generalized Anxiety Disorder
Lead Sponsor:
Universite du Quebec en Outaouais
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Concordia University, Montreal
Conditions:
Generalized Anxiety Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Generalized Anxiety Disorder (GAD) is a chronic condition that is characterized by excessive and uncontrollable worry and anxiety. In Canada, 3 to 4% of the population suffer from GAD at any point in ...
Eligibility Criteria
Inclusion
- at least 18 years of age;
- principal diagnosis of GAD;
- no change in medication type or dose in 4 to 12 weeks before study entry (4 weeks for benzodiazepines, 12 weeks for antidepressants and hypnotics);
- willingness to keep medication status stable while participating in the study;
- no use of herbal products known to have CNS effects in the 2 weeks before study entry;
- no evidence of suicidal intent (based on clinical judgement);
- no evidence of current substance abuse, current or past schizophrenia, bipolar disorder or organic mental disorder;
- no current participation in other trials;
- no concurrent psychotherapy during treatment phase of trial;
- no evidence of anxiety symptoms due to a general medical condition based on clinical judgement (e.g., clinical hyperthyroidism, hypoglycaemia, anaemia).
Exclusion
- \-
Key Trial Info
Start Date :
February 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2020
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT03433625
Start Date
February 8 2018
End Date
July 1 2020
Last Update
November 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universite du Quebec en Outaouais
Gatineau, Quebec, Canada, J8X 3X7